A psychiatric perspective on insomnia

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 10, 2001, Pages 27-32

  McCall, W Vaughn ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUVOXAMINE MALEATE; HYPNOTIC SEDATIVE AGENT; LORMETAZEPAM; MAPROTILINE; MELATONIN; NEFAZODONE; NORTRIPTYLINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIAZOLAM; VALERIAN; ZALEPLON; ZOLPIDEM TARTRATE;

BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MENTAL PATIENT; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SLEEP DISORDER;

ACETAMIDES; BENZODIAZEPINES; COMORBIDITY; DEPRESSIVE DISORDER; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPNOTICS AND SEDATIVES; MENTAL DISORDERS; PYRIDINES; PYRIMIDINES; RECEPTORS, GABA-A; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 0035017542     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey, I. Sleep 1999;22 (suppl 2):S347-S353
2. Haponik EF, Frye AW, Richards B, et al. Sleep history is neglected diagnostic information: challenges for primary care physicians. J Gen Intern Med 1996;11:759-761
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association; 1994
4. McCall WV, Reboussin BA, Cohen W. Subjective measurement of insomnia and quality of life in depressed inpatients. J Sleep Res 2000;9:43-48
5. McCall WV. A Practical Guide to Insomnia. Minneapolis, MN: McGraw-Hill Companies; 1999
6. Dryman A, Eaton WW. Affective symptoms associated with the onset of major depression in the community: findings of the US National Institute of Mental Health Epidemiologic Catchment Area Program. Acta Psychiatr Scand 1991;84:1-5
7. Wehr TA, Sack DA, Rosenthal NE. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 1987;144:201-204
8. Buysse DJ, Reynolds CF III, Hauri PJ, et al. Diagnostic concordance for DSM-IV sleep disorders: a report from the APA/NIMH DSM-IV field trial. Am J Psychiatry 1994;151:1351-1360
9. Ohayon MM. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res 1997;31:333-346
10. Conn JB, Bowden CL, Fisher JG, et al. Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med 1986;80 (suppl 3B):10-16
11. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine. and placebo in major depression. J Clin Psychiatry 1994;55:234-241
12. Gillin JC, Rapaport M, Erman MK, et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 1997;58:185-192. Correction 1997;58:275
13. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60:221-225
14. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colín R, et al. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997;58:348-350
15. Bemmel AL, Hoofdakker RH, Beersma DG, et al. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology 1993;113:225-230
16. Nowell PD, Reynolds CF III, Buysse DJ, et al. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry 1999;60:89-95
17. Armitage R, Emslie G, Rintelmann J. Effects of fluoxetine on sleep EEG in childhood depression [abstract]. Sleep Res 1997;26:369
18. Buysse DJ, Monahan JP, Cherry CR, et al. Persistent effects on sleep EEG following fluoxetine discontinuation [abstract]. Sleep Res 1997;26:370
19. Kupfer DJ, Spiker DG, Coble PA, et al. Amitriptyline and EEG sleep in depressed patients, I: drug effect. Sleep 1978;1:149-159
20. McCall WV, Cohen W, Reboussin B, et al. Effects of mood and age on quality of life in depressed inpatients. J Affect Disord 1999;55:107-114
21. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990;147:1189-1194
22. Agargün MY, Kara H, Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatry 1997;58:249-251
23. Reynolds CF III, Frank E, Houck PR, et al. Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication? Am J Psychiatry 1997; 154:958-962
24. Johns MW. Validity of subjective reports of sleep latency in normal subjects. Ergonomics 1997;20:683-690
25. Chervin RD, Aldrich MS, Pickett R, et al. Comparison of the results of the Epworth Sleepiness Scale and the Multiple Sleep Latency Test. J Psychosom Res 1997;42:145-155
26. Johns MW. A new method for measuring sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545
27. Schlote B, Schaaf L, Schmidt R, et al. Mental and physical state in subclinical hyperthyroidism: investigations in a normal working population. Biol Psychiatry 1992;32:48-56
28. Standards of Practice Committee of the American Sleep Disorders Association. Practice parameters for the use of polysomnography in the evaluation of insomnia. Sleep 1995;18:55-57
29. Morin CM, Culbert JP, Schwartz SM. Nonpharmacologic interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994; 151:1172-1180
30. Dashevsky BA, Kramer M. Behavioral treatment of chronic insomnia in psychiatric-ally ill patients. J Clin Psychiatry 1998;59:693-699
31. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1997;278:32-37
32. Mendelson WB. Efficacy of melatonin as a hypnotic agent. J Biol Rhythms 1997;12:651-656
33. Stevinson C, Ernst E. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med 2000;1:91-99
34. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999;22:371-375
35. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997; 278:2170-2177
36. Dealberto MJ, McAvay GJ, Seeman T, et al. Psychotropic drug use and cognitive decline among older men and women. Int J Geriatr Psychiatry 1997;12:567-574
37. Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997;278:27-31
38. Leveille SG, Buchner DM, Hoepsell TD, et al. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 1994;5:591-598
39. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262: 3303-3307
40. Tonne U, Hiltunen AJ, Vikander B, et al. Neuropsychological changes during steady-state drug use, withdrawal, and abstinence in primary benzodiazepine-dependent patients. Acta Psychiatr Scand 1995;91:299-304
41. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998;32:680-691
42. Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 1998;64:237-247
43. A receptors different from zolpidem, zopiclone, and benzodiazepines. Neuroscience Res Comm 1999;25:139-148
44. Elie R, Rüther E, Fair I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 1999;60:536-544
45. Walsh JK, Vogel GW, Scharf M, et al. A five-week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000;1:41-49
46. Monti JM. Effect of zolpidem on sleep in insomnia patients. Eur J Clin Pharmacol 1989;36:461-466
47. Ancoli-Israel S, Walsh JK, Mangano RM, et al. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Primary Care Companion J Clin Psychiatry 1999;1:114-120. Correction 1999;1:193
48. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep 1995;18: 246-251
49. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-199
50. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992;20:150-161
51. Kummer J, Linden J, Eich FX, et al. Long-term polysomnographic efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res 1993;21:171-184
52. Asnis GM, Chakraburtly A, Duboff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999;60: 668-676
53. Hajak G, Adler L, Bandelow B, et al. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry 1996;29:187-192
54. Cluydts R, Peeters K, Bouyalsky I, et al. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res 1998;26:13-24
55. Zolpidem. Physicians Desk Reference. Montvale, NJ: Medical Economics 2001:2627
56. Danjou P, Paty I, Fruncillo R, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 and 2 h before awakening. Br J Clin Pharmacol 1999;48:367-374
57. Vermeen A, Danjou PE, O'Hanlon JF. Residual driving effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacology 1998; 13(suppl):98-107
58. Stepanski E, Korshorek G, Zorick F, et al. Characteristics of individuals who do or do not seek treatment for chronic insomnia. Psychosomatics 1989;30:421-427
59. Schlich D, L'Heritier C, Coquelin JP, et al. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 1991;19:271-279
60. Maarek L, Cramer P, Coquelin JP, et al. The safety and efficacy of zolpidem in insomnia patients: a long-term open study in general practice. J Int Med Res 1991;20:162-170
61. Zaleplon. Physicians Desk Reference. Montvale, NJ: Medical Economics 2001: 3451
62. Cook MD, Conner J. Retrospective review of hypnotic use in combination with fluoxetine and sertraline. Clin Drug Invest 1995;9:2112-2116
63. Nolen WA, Haffmans PMJ, Bouvy PF, et al. Hypnotics as concurrent medication in depression. J Affect Disord 1993;28:179-188
64. Dominguez RA, Jacobson AF, Goldstein BJ, et al. Comparison of triazolam and placebo in the treatment of depressed patients. Curr Ther Res 1984; 36:856-865
65. Conn JB. Triazolam treatment in depressed patients taking tricyclics. J Clin Psychiatry 1983;44:401-406
66. Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zopiclone, and zolpidem. Cell Mol Neurobiol 1999;19:533-552
67. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000;59: 865-889
68. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320
69. Kawashima K, Hosoi K, Naruke T, et al. Aldehyde oxidase-dependent marked species differences in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metab Dispos 1999;27: 422-428